Dermata Therapeutics, Inc.
DRMA Nasdaq
SEC CIK 1853816
Follow Dermata Therapeutics
Weekly email: filings, results
Revenue, last quarter
$74.1K
Net income
−$2.8M
−66.8% vs same quarter last year
EPS, diluted
−$0.55
+66.7% vs same quarter last year
Operating cash flow
−$2.6M
−46.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$7.6M |
| FY24 | −$12.3M |
| FY23 | −$7.8M |
| FY22 | −$9.6M |
| FY21 | −$7.9M |
| FY20 | −$3.2M |
| FY19 | - |